All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL
On March 25, 2021, it was announced that duvelisib received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and refractory follicular lymphoma (FL).1
Duvelisib is a dual inhibitor of PI3K-δ and PI3K-γ; therefore, it blocks the proliferation and survival of malignant B-cell lines and primary CLL tumor cells, as well as immunological pathways in the tumor microenvironment of malignant B cells.1
Duvelisib has already been granted approval by the U.S. Food and Drug Administration (FDA) for patients with R/R FL and patients with R/R CLL or small lymphocytic lymphoma, which was based on the DYNAMO (NCT01882803) and DUO (NCT02004522) trial results.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?